OTC : ESAIY

Eisai Co., Ltd.

$7.46 USD

-$0.39 (-4.97%)

Volume
19.12K
Average Volume
230.98K
Market Capitalization
$8.42B
P/E Ratio
35.31
Dividend Yield
3.31%
Price Target
Year High
$9.22
Year Low
$5.69
Day High
—
Day Low
—
Payout Ratio
$1.17
Current Ratio
$2.24
Company Overview

OTC

Haruo Naito

Drug Manufacturers - Specialty & Generic

Healthcare

ESAIY

10543

JP

USD

https://www.eisai.com

81 3 3817 3700

28258A107

N/A

Liquidity Metrics

0.21

2.24

1.48

0.72

1.17

Sales & Valuation

$825.38B

1.65

1.51

29.63

40.76

Profitability

$34.2

$38.56B

4.67%

6.18%

4.44%

2.66%

P/E Metrics

35.31

-2.14

-2.14

Analyst Price Target & Rating

Neutral

3/5

0 Analysts

%

Financial Health Scores

3.05

7/9

$423.21B

$1.46T

$526.26B

$53.23B

Key Metrics (TTM)

$1.3T

1.58

13.59

2.24

4.44%

2.75%

2.83%

3.37%

$3132.92

447 days

Company Executives
Name Title
Yanhui Feng Senior Vice President
Terushige Iike Executive VP, Rep. Corporate Officer & Chief Business Officer
Akiko Nakahama Vice President of Japan Regulatory Affairs, Manufacturing, Quality & Technology
Takuya Oyama Vice President, Chief Financial Officer & Chief IR Officer
Teruyuki Masaka Vice President and Chief HR Officer, Corporate Communications, Sustainability & General Affairs
Makoto Hoketsu Vice President & Chief Information Officer
Haruo Naito Chief Executive Officer, Representative Corporate Officer & Director
Shin Kato Vice President, General Counsel & Chief Compliance Officer
Keisuke Naito Representative Corporate Officer, EVice President, Chief Operating Officer & Chief Growth Officer
Katsutoshi Ido Vice President, Chief Scientific Officer & Head of DHBL Discoverry
Lynn D. Kramer FAAN Vice President & Chief Clinical Officer
Poll Results

No votes yet today — be the first to share your view!

About Eisai Co., Ltd. (OTC:ESAIY) Stock

Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. Its comprehensive product portfolio includes prominent medications such as Dayvigo, prescribed for insomnia, and the potent anticancer drug Lenvima, a molecularly targeted therapy effective against thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma when paired with everolimus. The company also markets Methycobal for peripheral neuropathy and Halaven, another anticancer agent targeting breast cancer. Further offerings encompass Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid formulation; Goofice and Movicol, utilized for managing chroni ... c constipation; Fycompa, an antiepileptic; Pariet, a proton-pump inhibitor; and Aricept, a treatment for Alzheimer's and Dementia with Lewy bodies. Additionally, it produces Chocola BB plus, a vitamin B2 supplement. Eisai maintains a strategic alliance with Bristol Myers Squibb, focusing on the joint development and commercialization of the antibody drug conjugate, farletuzumab ecteribulin. Established in Tokyo, Japan, in 1941, the company was initially known as Nihon Eisai Co., Ltd. before adopting its current name, Eisai Co., Ltd., in 1955.

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

2026-07-13 15:02:12

The U.S. FDA on Monday approved an ​at-home starting dose of Eisai's and Biogen's Alzheimer's drug, ‌allowing some patients to begin therapy with injections administered by themselves or a caregiver.

Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript

2026-05-25 10:47:04

Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript

Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript

2026-05-15 12:50:46

Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Eisai Co., Ltd. (ESAIY) stock price?

Eisai Co., Ltd.(OTC:ESAIY) stock price is $7.46 in the last trading session. During the trading session, ESAIY stock reached the peak price of $9.22 while $5.687 was the lowest point it dropped to. The percentage change in ESAIY stock occurred in the recent session was --4.97% while the dollar amount for the price change in ESAIY stock was -$0.39.

ESAIY's industry and sector of operation?

The OTC listed ESAIY is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of ESAIY?

Yanhui Feng | Senior Vice President
Terushige Iike | Executive VP, Rep. Corporate Officer & Chief Business Officer
Akiko Nakahama | Vice President of Japan Regulatory Affairs, Manufacturing, Quality & Technology
Takuya Oyama | Vice President, Chief Financial Officer & Chief IR Officer
Teruyuki Masaka | Vice President and Chief HR Officer, Corporate Communications, Sustainability & General Affairs

How many employees does ESAIY have?

Number of ESAIY employees currently stands at 10543. ESAIY operates from 4-6-10, Koishikawa, Tokyo, TY 112-8088, JP.

Link for ESAIY official website?

Official Website of ESAIY is: https://www.eisai.com

How do I contact ESAIY?

ESAIY could be contacted at phone #81 3 3817 3700 and can also be accessed through its website. ESAIY operates from 4-6-10, Koishikawa, Tokyo, TY 112-8088, JP.

How many shares of ESAIY are traded daily?

The average number of ESAIY shares traded daily for last 3 months was 230.98K.

What is the market cap of ESAIY currently?

The market value of ESAIY currently stands at $8.42B with its latest stock price at $7.46